- Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs
- Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for three of the company’s four products and pending clinical testing
- Odyssey’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder and patients needing treatment for brain concussion injuries
- The drug-device combination for treating concussions is advancing in a Phase 1 clinical human trial that is currently enrolling 48 patients
Sixty-five years after retired business and senior finance executive Bob Valentine received life-saving care in Children’s Hospital of Buffalo’s neonatal intensive care unit (“NICU”) to treat respiratory distress syndrome he experienced as a newborn, Valentine made a Valentine’s Day donation of $500,000 this year to the hospital’s foundation, which established a fund to help families experiencing a similar journey (https://ibn.fm/VbhyF).
Valentine’s expression of gratitude for what was then revolutionary medical care is by no means unique in the annals of emergency treatments that have helped patients overcome traumatic developments and go on to pursue their lives. A Long John Silver’s business executive recently gifted $1 million to…
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.